Cagrilintide – 10 Vials (CAS: 1415456-99-3)

$395.00

Cagrilintide is a long-acting amylin analogue and dual amylin/calcitonin receptor agonist (DACRA) researched for its effects on appetite regulation, body weight, and glycaemic control. This high-purity lyophilized powder is a valuable tool for investigating amylin receptor biology, satiety signalling, and metabolic regulation. Supplied for laboratory research use only.

SKU PEP-CAGRILINTIDE-US Categories ,

Description

Cagrilintide is a synthetic long-acting analogue of human amylin, a hormone co-secreted with insulin from pancreatic beta-cells that regulates satiety and glucose homeostasis. It functions as a dual agonist at amylin receptors (AMYRs) and calcitonin receptors (CTR), a mechanism that distinguishes it from other amylin-based compounds.

This product is supplied as a sterile lyophilized powder and is intended strictly for research purposes only. It is NOT for human or veterinary consumption.

 

Key Research Focus

Cagrilintide has been the subject of extensive preclinical and clinical research exploring its metabolic properties:

  • Mechanism of Action and Receptor Binding: Cagrilintide activates Gs signalling pathways through both amylin receptors (AMY1R, AMY2R, AMY3R) and calcitonin receptors (CTR). Structural studies reveal it adopts an “amylin-like” binding mode with distinct conformational dynamics at calcitonin-family receptors, including a key F23 residue that anchors the peptide at the receptor transmembrane bundle level. In vivo research demonstrates that brain amylin receptors (AMY1R and AMY3R) are necessary for cagrilintide-mediated body weight loss.
  • Appetite Regulation and Body Weight: Cagrilintide reduces food intake and induces bodyweight reduction in preclinical and clinical studies. Research in diet-induced obese (DIO) rodent models has characterised its effects on energy balance through the dorsal vagal complex (DVC), a key brainstem region for satiety signalling.
  • Clinical Efficacy in Obesity and Type 2 Diabetes: Cagrilintide is being developed as a monotherapy and in fixed-dose combination with semaglutide (CagriSema). In the Phase 3 REDEFINE 1 trial, cagrilintide–semaglutide (2.4 mg each) produced a mean body weight reduction of –20.4% at week 68 versus –3.0% with placebo. In the REIMAGINE 2 trial in type 2 diabetes, cagrilintide–semaglutide (2.4 mg each) achieved superior HbA1c reduction versus semaglutide alone (–1.91 vs –1.75 percentage points). The most common adverse events were gastrointestinal, consistent with the GLP-1 receptor agonist class.
  • Distinct Glycaemic Mechanisms: Evidence suggests cagrilintide may enhance insulin sensitivity, while semaglutide increases insulin secretion, providing complementary glycaemic benefits when co-administered.
  • Kidney Physiology Research: Preliminary ex vivo studies in diabetic ZDF rats demonstrate that cagrilintide elevates intracellular cAMP in cortical tubules and modulates ion transporter phosphorylation (NKCC2, NCC) in the distal nephron, suggesting a diabetes-specific mechanism of action in kidney physiology.

 

Product Specifications

  • Form: Lyophilized Powder (Sterile)
  • Purity: >95–98% (HPLC Verified)
  • Storage: Store at -20°C (freezer) for long-term stability. Protect from light.
  • Solubility: Soluble in sterile water or buffer for laboratory use.
  • Disclaimer: This product is a chemical reagent for research purposes only. It is NOT for human or animal consumption, diagnostic, or therapeutic use.

 

Why Choose Cagrilintide?

Cagrilintide offers a mechanistically distinct research tool for studying amylin receptor biology and metabolic regulation. Unlike GLP-1 receptor agonists, it activates amylin and calcitonin receptors through a “bypass” binding mode, providing researchers with a complementary pathway to investigate satiety signalling, energy homeostasis, and glucose regulation. Its well-characterised receptor pharmacology, extensive Phase 3 clinical data, and demonstrated effects on body weight and glycaemic control make it a valuable reagent for metabolic and obesity research.

Additional information

Grams

10mg

Disclaimer: Supplied strictly as a high-purity chemical reagent for laboratory research and development use only. Not for human or animal consumption.

Our Products